Trial Profile
A Phase I, randomized, double-blind, placebo-controlled single and multiple ascending dose program study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral LSD1-MAOB dual selective inhibitor ORY-2001 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2021
Price :
$35
*
At a glance
- Drugs Vafidemstat (Primary)
- Indications Aggression; Alzheimer's disease; Autistic disorder; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Schizophrenia; Telomeric 22q13 Monosomy Syndrome
- Focus Adverse reactions; First in man
- Sponsors Oryzon
- 24 Mar 2021 Results published in the Media Release
- 23 Mar 2021 Results published in the CNS Drugs
- 24 Jul 2017 According to an Oryzon media release, with the approval of the Spanish Medicines Agency (AEMPS), an additional cohort of volunteers was added to be administered at a higher dose of ORY-2001 to complete the hematological safety profile of the product, as well as two additional cohorts to determine the levels of the drug in cerebrospinal fluid.